Close

BrainScan SA

ul. Kieturakisa 10
80-742 Gdansk
Poland
VAT-ID: PL 5862321880

About us

About

Meet our teamTeam

Team members
0 +

Initial Public Offering (IPO) on the Warsaw Stock Exchange (WSE)IPO

Funding Milestones - From Seed to Growth

BrainScan has secured multiple rounds of funding, including a recent €2.5 million grant from the Polish Agency for Enterprise Development (PARP) to support the development of its multimodal diagnostic platform. In May 2024, BrainScan CT became a publicly traded company on the Warsaw Stock Exchange’s NewConnect market under the ticker symbol BSN.

/ We revolutionized the analysis of human brain ct scans through AI. 
/ We revolutionized the analysis of human brain ct scans through AI. 

historyCompany History and Strategic Plans

2025
FDA Certification, U.S. Patent, and International Research Collaborations

In 2025, BrainScan targets FDA certification and U.S. patent approval, enabling entry into the American medical market and reinforcing its innovation leadership. The company also continues scientific research in collaboration with the Provincial Hospital in Poznan and LMU Hospital in Munich. These partnerships support clinical validation and help refine upcoming features, including automated report generation planned for 2026 to streamline radiologists' workflows.

2024
30 Brain Pathologies Detected and First On-Premise Deployment

In 2024, BrainScan expanded its AI capabilities to detect 30 key brain pathologies, making it one of the most comprehensive tools in neuroimaging. The company also completed its first full on-premise installation, offering hospitals full data control and local AI-powered diagnostics.

2023
First EU Launch and CE MDR Approval

In 2023, BrainScan completed its first implementation in a European hospital outside Poland. That same year, the company received CE MDR 2017/745 certification, enabling full compliance with updated EU medical device regulations.

2018-2021
CE Certification and RSNA Gold Medal

Between 2018 and 2021, BrainScan received CE certification for its AI-powered diagnostic system. The company also won the Gold Medal at RSNA in the U.S., confirming its global innovation leadership in radiology AI solutions.

2017
Establishing Company

BrainScan was founded in 2017 to revolutionize brain CT diagnostics using AI. The company began developing its own deep learning system for detecting critical brain pathologies in CT scans, setting the foundation for future clinical use and certification.

testimonialsHear what our customers say about our AI solutions

Installed in healthcare facilities, ERs, and brain imaging centers
0 +

get in touchWe are always ready to help you and answer your questions

BrainScan SA
office:

ul. Kieturakisa 10
80-742 Gdansk
Poland
VAT-ID: PL5862321880

Email:
BrainScan SA
software development center:

ul. Traugutta 75
80-221 Gdansk
Poland

Social networks: